A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. An open label, randomized, pha...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Kim, Hye Ryun, Jang, Joung Soon, Sun, Jong-Mu, Ahn, Myung-Ju, Kim, Dong-Wan, Jung, Inkyung, Lee, Ki Hyeong, Kim, Joo-Hang, Lee, Dae Ho, Kim, Sang-We, Cho, Byoung Chul
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Clinical Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362536/
https://ncbi.nlm.nih.gov/pubmed/27823977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13056
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы